BRIEF-Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
Reuters2026/09/23 11:04Roivant Sciences Ltd ROIV.O:
ROIVANT ANNOUNCES TOPLINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF IMVT-1402 IN CUTANEOUS LUPUS ERYTHEMATOSUS
ROIVANT SCIENCES - IMVT-1402 STUDY IN CLE DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
ROIVANT SCIENCES - IMMUNOVANT TO STOP DEVELOPMENT OF IMVT-1402 IN CLE
ROIVANT SCIENCES - IMVT-1402 DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
ROIVANT SCIENCES - ALL OTHER CLINICAL DEVELOPMENT TIMELINES REMAIN ON TRACK
Source text: ID:nGNX559XzF
Further company coverage: ROIV.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nidec shares plunge 17%
BoJ Minutes: Members agree financial conditions remain accommodative
Iran’s seven-day reopening plan for the Hormuz Strait was rejected by Trump; Brent crude oil rises above $106
Iran insists on a seven-day proposal to reopen the Strait of Hormuz, but this plan has been rejected by U.S. President Trump, which may further delay the reopening of this crucial waterway.
New York Silver Futures Drop 1% to $64.15 per Ounce
Crypto prices
More
